Facebook
Twitter
LinkedIn
Forward
21st Annual International Ultmann Chicago Lymphoma Symposium
Chicago, IL US
April 19, 2024 to April 20, 2024
The 21st International Ultmann Chicago Lymphoma Symposium (IUCLS) is a continuation of an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
We are fortunate to have a multitude of the world’s experts in lymphoma speak each year at the conference. The audience is comprised of national practicing oncologists, advanced nurse practitioners and physician assistants, nurses, residents, fellows, and the Chicago academic community that includes five academic centers. This year’s program will be offered live on April 19-20, 2024, and represents the 21st IUCLS.
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. The format of the meeting includes a combination of expert presentations, interactive case discussions, poster and abstract presentations, and an opportunity for question-and-answer debates. Additionally, the entire conference will be certified for nursing continuing education credits.
The goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma.
IUCLS will gather both domestic and international clinicians and researchers specializing in the treatment of patients with lymphoma.
This event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.
Target Audience
This activity is designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and other healthcare professionals interested in the treatment and diagnosis of lymphoma.
Learning Objectives
At the conclusion of this educational activity, participants will be able to:
- Evaluate the latest treatment strategies for patients with indolent and aggressive forms of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma;
- Assess the safety and efficacy of current and emerging therapeutic approaches for the care of patients with Hodgkin lymphoma;
- Compare and contrast the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL;
- Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma;
- Develop strategies to communicate with and utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.
You may also be interested in
Westin Chicago River North
320 N Dearborn St
Chicago, IL
60654
United States
WANT TO KNOW MORE?
Learn more about the program by visiting the symposium website!
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office via e-mail at iucls@bioascend.com.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
SYMPOSIUM CO-CHAIRS
Sonali M. Smith, MDElwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Andrew M. Evens, DO, MBA, MScProfessor of Medicine, Rutgers Robert Wood Johnson Medical School
Associate Director for Clinical Services, Rutger Cancer Institute of New Jersey
Director, Lymphoma Program, Division of Blood Disorders
Medical Director, Oncology Service Line, RWJBarnabas Health
Medical Director, Oncology Service Line, RWJBarnabas Health
Medical College of Wisconsin
Milwaukee, Wisconsin
Milwaukee, Wisconsin
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of continuing nursing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 13.75 contact hours.
Participants who successfully complete the entire activity and complete an evaluation form will earn 13.75 contact hours.
American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Health Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other Health Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: Requests to claim MOC Part II credit must be made within one month to report to ABIM. Requests to claim AMA PRA Category 1 Credit™ after three months will be subject to additional fees.
REGISTRATION
Click the button below for complete registration information and to register. Early bird registration will end on March 19, 2024!
Onsite Registration Available!
Proof of COVID-19 vaccination status is not required to register or attend the conference. However, we strongly recommend staying up to date with CDC vaccine recommendations. To ensure the safety of all attendees, and because of ongoing health risks, particularly to the unvaccinated, participants are expected to adopt the risk mitigation measures (masking and social distancing, etc.) appropriate to their vaccination status as advised by public health officials or to their individual vulnerabilities as advised by a medical professional. Public convening may not be safe for all and carries a risk for contracting COVID-19, particularly for those unvaccinated. Participants will not know the vaccination status of others and should follow appropriate risk mitigation measures.
For questions or concerns, please contact iucls@bioascend.com.
Proof of COVID-19 vaccination status is not required to register or attend the conference. However, we strongly recommend staying up to date with CDC vaccine recommendations. To ensure the safety of all attendees, and because of ongoing health risks, particularly to the unvaccinated, participants are expected to adopt the risk mitigation measures (masking and social distancing, etc.) appropriate to their vaccination status as advised by public health officials or to their individual vulnerabilities as advised by a medical professional. Public convening may not be safe for all and carries a risk for contracting COVID-19, particularly for those unvaccinated. Participants will not know the vaccination status of others and should follow appropriate risk mitigation measures.
For questions or concerns, please contact iucls@bioascend.com.
Symposium and Interprofessional Session
| Profession Type | Early Bird Fee | After Early Bird Fee |
|---|---|---|
| Physician/PharmD/PhD | $325 | $375 |
| Nurse/OHP | $150 | $175 |
| Fellow/Resident/Student | $125 | $150 |
| Pharma Industry/Representative | $600 | $750 |
Symposium ONLY
| Profession Type | Early Bird Fee | After Early Bird Fee |
|---|---|---|
| Physician/PharmD/PhD | $275 | $325 |
| Nurse/OHP | $125 | $150 |
| Fellow/Resident/Student | $100 | $125 |
| Pharma Industry/Representative | $450 | $500 |
Nursing Session ONLY
| Profession Type | Early Bird Fee | After Early Bird Fee | |
|---|---|---|---|
| Physician/PharmD/PhD | $100 | $150 | |
| Nurse/OHP | $75 | $100 | |
| Fellow/Resident/Student | $75 | $100 | |
| Pharma Industry/Representative | $150 | $200 | |
CANCELLATION POLICY: See website for complete information. | |||
CLAIMING CREDIT
After the conference, create an account or log in and enter the access code to unlock the credit claiming process.
Please Note: Requests to claim MOC Part II credit must be made within one month to report to ABIM. Requests to claim AMA PRA Category 1 Credit™ after three months will be subject to additional fees.
Please login or create an account to proceed.